- Suppliers
ADM 
Armor Pharma 
Asahi KASEI 
Ashland 
BASF 
Beneo 
Captisol 
Clariant 
Croda 
DFE Pharma 
Excipio Chemicals 
Fuji Chemical 
Gattefossé 
Gangwal 
IamFluidics 
IOI Oleo 
Ingredient Pharm 
JRS Pharma 
Kerry 
KLK Oleo 
Lipoid 
Lubrizol Life Science Health 
MAGNESIA 
MEGGLE 
Nagase Viita 
Nordic Bioproducts 
Pfanstiehl 
pharm-a-spheres 
PMC Isochem 
Seppic 
ShinEtsu 
Sigachi 
SPI Pharma 
Südzucker 
Vikram Thermo 
Zerion Pharma 
All4Nutra
- Suppliers
ADM Armor Pharma Asahi KASEI Ashland BASF Beneo Captisol Clariant Croda DFE Pharma Excipio Chemicals Fuji Chemical Gattefossé Gangwal IamFluidics IOI Oleo Ingredient Pharm JRS Pharma Kerry KLK Oleo Lipoid Lubrizol Life Science Health MAGNESIA MEGGLE Nagase Viita Nordic Bioproducts Pfanstiehl pharm-a-spheres PMC Isochem Seppic ShinEtsu Sigachi SPI Pharma Südzucker Vikram Thermo Zerion Pharma - All4Nutra
Solid-Lipid Nanoparticle (SLN) Based Approaches for Enhancing the Therapeutic Efficacy of Anticancer Drugs in Targeting Gastrointestinal Malignancies
Solid-Lipid Nanoparticle (SLN) Based Approaches for Enhancing the Therapeutic Efficacy of Anticancer Drugs in Targeting Gastrointestinal Malignancies
Abstract
Solid lipid nanoparticles (SLNs) exhibit excellent potential as a drug delivery system in treating several cancers including gastrointestinal (GI) malignancies. SLNs offer potential advantages over conventional drug delivery methods in terms of their superior physicochemical and biological characteristics. In GI malignancies, SLNs are advantageous for advanced targeting, decreased systemic toxicity, and increased therapeutic effect of anticancer drugs due to their distinctive physicochemical properties, such as biocompatibility, ability to entrap both hydrophilic and lipophilic drugs, and sustained release potential.
Highlights
- Potential of SLNs as a novel drug delivery system for innovative approaches in diagnosing and treating GI malignancies.
- Overcoming limitations of traditional therapies such as poor solubility and nonspecific biodistribution.
- SLNs establish to improve targeting and release profiles while addressing challenges including low drug absorption rates and drug degradation in acidic environments.
- Leaky vasculature of tumors allows SLNs to passively target tumor cells to improve enhanced permeability and retention time of drugs.
This review elaborates the unique applications of SLNs in treating GI malignancies including Esophageal, gastric, colorectal, liver, and pancreatic cancers, focusing on their ability to overcome the limitations of conventional modules such as poor bioavailability, rapid drug metabolism, decreased intestinal absorption and resistance mechanisms developed by the tumor cells. Through the use of SLNs for delivering chemotherapeutic drugs, RNA-based therapies, and immunomodulators, several advantages are offered in the management of GI cancers in terms of improved clinical outcomes and decreased side effects.
The challenges and future perspectives for the clinical translation of SLNs in GI malignancies are also apprised, highlighting the need for research and optimization of formulation strategies. SLN-based nanocarrier systems offer a unique platform for prospective applications in the delivery of anticancer drugs in the form of targeted therapeutics.
Continue reading here
Gaurav R, M., Prabhu, A. Solid-Lipid Nanoparticle (SLN) Based Approaches for Enhancing the Therapeutic Efficacy of Anticancer Drugs in Targeting Gastrointestinal Malignancies. J Pharm Innov 21, 24 (2026). https://doi.org/10.1007/s12247-025-10138-w
Read more on the World Cancer Day 2025:
